📰 Former Parent News
Former Parent News Today
Fast, Ad-Free News Updates
Stay updated with breaking news from Former Parent. Real-time updates on events, politics, business and more.
February 29, 2024
NORTH BETHESDA, Md., February 29, 2024--ESAB Corporation Announces Fourth Quarter 2023 Results and Initiates Full Year 2024 Guidance
February 29, 2024
NEW YORK, Feb. 29, 2024 -- FTAI Infrastructure Inc. today reported financial results for the fourth quarter and full year 2023. The Company’s consolidated comparative financial statements and...
February 21, 2024
PHINIA Inc. , a leader in premium fuel systems, electrical systems, and aftermarket products, today reported its fourth quarter and full year ended December 31, 2023 results. Fourth Quarter...
February 6, 2024
/PRNewswire/ -- Veralto (NYSE: VLTO) (the "Company"), a global leader in essential water and product quality solutions dedicated to Safeguarding the Worlds...
November 13, 2023
13.11.2023 - Xperi Inc. (NYSE: XPER) (the “Company” or “Xperi”), an entertainment technology company that invents, develops, and delivers technologies that enable extraordinary experiences, today announced financial results for the third quarter ended September ...
September 22, 2023
Revenues increased 137%; company completed a $7.8 Million Initial Public Offering in July 2023...
August 14, 2023
14.08.2023 - For the three months ended June 30, 2023: Revenues of $793.0 millionGAAP net income of $28.3 millionAdjusted EBITDA of $72.5 millionGAAP and adjusted earnings per share of $0.32 and $0.52, respectively Provides full-year financial outlook DURHAM, ...
August 1, 2023
Record sales and margin performance Sales up 9% with core organic growth of 6% Reported net income from continuing operations attributable to ESAB of $67 million and core adjusted EBITDA of...
July 25, 2023
NEW YORK, July 25, 2023 -- FTAI Infrastructure Inc. today reported financial results for the second quarter 2023. The Company’s consolidated comparative financial statements and key performance...
May 12, 2023
Acquired exclusive license for oral, brain-penetrant, dual TYK2/JAK1 inhibitor for immune-mediated brain disorders in March 2023 covering global rights...